Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Trimeris Focuses On Profitability
November 20, 2006
| A version of this story appeared in
Volume 84, Issue 47
Trimeris will cut an undisclosed number of jobs by the end of the year as part of a plan for increasing and sustaining earnings from its HIV treatment Fuzeon. The firm says the goal is to improve the profitability of Fuzeon by "sharply reducing expenses." By 2007, Trimeris expects to generate more than $1.00 per share in earnings for an additional $20 million of cash flow each year. As part of the shift, Steven Skolsky is stepping down as CEO. Dani Bolognesi, chief scientific officer and cofounder of the company, will return to the CEO position.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X